

Application. No. 09/728,420.
Amdt. dated April 1, 2005
Reply to Office Action of October 1, 2004

PATENT APPLICATION**Please amend the claims as follows.**

1-55. (cancelled)

56. (currently amended) A polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from one or more of:

- a) a nucleotide sequence as set forth in Figure 2A (SEQ ID NO: 6);
- b) a nucleotide sequence encoding the polypeptide as set forth in Figure 2A (SEQ ID NO: 7) from residues 1-322 or from residues 47-322;
- c) a nucleotide sequence encoding a polypeptide that is at least about 95 percent identical to the polypeptide as set forth in Figure 2A (SEQ ID NO: 7), wherein the isolated polypeptide has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22);
- d) a nucleotide sequence of (b) or (c) encoding a polypeptide fragment of Figure 2A (SEQ ID NO:7) from residues 1-322 or from 47-322 wherein the polypeptide fragment is at least about 50 amino acid residues and has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22);
- e) ~~a nucleotide sequence comprising~~ a fragment of at least about 75 nucleotides of the sequence as set forth in Figure 2A (SEQ ID NO:6) wherein the ~~polypeptide fragment~~ encodes a polypeptide having has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22); and
- f) a nucleotide sequence fully complementary to any of (a)-(e).

57. (currently amended) A polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from one or more of:

- a) a nucleotide sequence as set forth in Figure 3A (SEQ ID NO: 11);
- b) a nucleotide sequence encoding the polypeptide as set forth in Figure 3A (SEQ ID NO: 12) from residues 1-288 or from residues 19-288, 20-288, 21-288, 22-288, 24-288 or 28-288;
- c) a nucleotide sequence encoding a polypeptide that is at least about 95 percent identical to the polypeptide as set forth in Figure 3A (SEQ ID NO: 12), wherein the isolated polypeptide has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22);
- d) a nucleotide sequence of (b) or (c) encoding a polypeptide fragment of residues 1-288 in Figure 3A (SEQ ID NO:12) wherein the fragment is at least about 50 amino acid residues and

Application No. 09/728,420
Amdt. dated April 1, 2005
Reply to Office Action of October 1, 2004

PATENT APPLICATION

has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22);

e) ~~a nucleotide sequence comprising~~ a fragment of at least about 75 nucleotides of the sequence as set forth in Figure 3A (SEQ ID NO:11) wherein the ~~polypeptide fragment encodes a~~ polypeptide having has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22); and

f) a nucleotide sequence fully complementary to any of (a)-(e),
wherein the nucleotide sequence does not encode the polypeptide of GenBank Accession No. AB014553.

58. **(currently amended)** An isolated polypeptide comprising an amino acid sequence selected from one or more of:

- a) an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7);
- b) a mature amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7) comprising a mature amino terminus at residue 47; and
- c) a fragment of an amino acid sequence set forth in Figure 2A (SEQ ID NO: 7) from residues 1-322 wherein the fragment ~~comprises~~ is at least about 50 amino acid-residues and has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22).

59. **(currently amended)** An isolated polypeptide comprising an amino acid sequence selected from one or more of:

- a) an amino acid sequence as set forth in Figure 3A (SEQ ID NO: 12);
- b) a mature amino acid sequence as set forth in Figure 3A (SEQ ID NO: 12) comprising a mature amino terminus at any of residues 19, 20, 21, 22, 24 or 28, or as set forth in Figure 12A (SEQ ID NO: 17) comprising a mature amino terminus at any of residues 19,20,21,22,24,or 28; and
- c) a fragment of an amino acid sequence set forth in Figure 3A (SEQ ID NO: 12) from residues 1-288 wherein the fragment comprises an extracellular domain or portion thereof at least about ~~50 amino acid residues~~ and has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22),
wherein the polypeptide does not have the amino acid sequence in GenBank Accession No. AB014553.

Application No. 09/728,420
Amdt. dated April 1, 2005
Reply to Office Action of October 1, 2004

PATENT APPLICATION

60. **(currently amended)** A composition comprising a polypeptide and a pharmaceutically acceptable carrier, adjuvant, solubilizer, stabilizer or anti-oxidant, wherein the polypeptide is the isolated polypeptide of Claims 56, 57, 58 or [-]59.

61. **(currently amended)** A polypeptide comprising a derivative of a polypeptide of Claims 56, 57, 58 or [-]59 which is modified with one or more chemical groups.

62. **(currently amended)** The polypeptide of Claim 61 which is ~~covalently~~ modified with a water-soluble polymer.

63. **(currently amended)** A fusion polypeptide comprising a polypeptide of Claims 56, 57, 58 or [-]59 fused to a heterologous amino acid sequence.

64. **(previously presented)** The fusion polypeptide of Claim 63 wherein the heterologous amino acid sequence is an IgG constant domain or fragment thereof.

65. **(previously presented)** An isolated polypeptide of Claim 58 comprising the amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7).

66. **(previously presented)** An isolated polypeptide of Claim 58 consisting of an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7).

67. **(currently amended)** ~~The isolated polypeptide of Claim 58~~ A polypeptide comprising a fragment of an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7) ~~comprising at least about 50 amino acid residues~~, wherein the fragment comprises an extracellular domain and has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22).

68. **(currently amended)** ~~An isolated~~ A polypeptide comprising an amino acid sequence that is at least about 95 percent identical to an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 6) wherein the isolated polypeptide has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22).

69. **(currently amended)** ~~An isolated~~ A polypeptide ~~comprising a fragment of at least about 50 amino acid residues, wherein the fragment comprises of an amino acid sequence that is at least about 95 percent identical to an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 6) and~~

Application No. 09/728,420
Amdt. dated April 1, 2005
Reply to Office Action of October 1, 2004

PATENT APPLICATION

wherein the fragment has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22).

70. **(previously presented)** The isolated polypeptide of Claim 59 comprising the amino acid sequence as set forth in Figure 3A (SEQ ID NO: 12) wherein the polypeptide does not have the amino acid sequence of GenBank Accession No. AB104553.

71. **(previously presented)** The isolated polypeptide of Claim 59 consisting of an amino acid sequence as set forth in Figure 3A (SEQ ID NO: 12).

72. **(currently amended)** An isolated A polypeptide comprising a fragment of an amino acid sequence as set forth in Figure 3A (SEQ ID NO: 12) ~~comprising at least about 50 amino acid residues,~~ wherein the fragment comprises an extracellular domain and has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22), wherein the polypeptide does not have the amino acid sequence in GenBank Accession No. AB014553.

73. **(currently amended)** An isolated polypeptide comprising an amino acid sequence that is at least about 95 percent identical to an amino acid sequence as set forth in Figure 3A (SEQ ID NO: 12), wherein the isolated polypeptide has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22), wherein the polypeptide does not have the amino acid sequence in GenBank Accession No. AB014553.

74. **(currently amended)** An isolated A polypeptide comprising a fragment of at least about 50 amino acid residues, ~~wherein the fragment comprises of~~ an amino acid sequence that is at least about 95 percent identical to an amino acid sequence as set forth in Figure 3A (SEQ ID NO: 12), and wherein the fragment has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22), ~~wherein the polypeptide does not have the amino acid sequence in GenBank Accession No. AB014553.~~

75. **(currently amended)** An isolated polypeptide comprising an amino acid sequence as set forth in Figure 12A (SEQ ID NO:17) with a mature amino terminus at any of residues 19, 20, 21, 22, 24 or 28, wherein the isolated polypeptide has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22).

Application. No. 09/728,420
Amdt. dated April 1, 2005
Reply to Office Action of October 1, 2004

PATENT APPLICATION

76. **(currently amended)** An isolated polypeptide comprising an amino acid sequence as set forth in Figure 12A (SEQ ID NO:17) comprising a carboxy terminus at residue 302, wherein the isolated polypeptide has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22).

77. **(previously presented)** An isolated polypeptide comprising an amino acid sequence as set forth in Figure 12A (SEQ ID NO:17).

78. **(previously presented)** An isolated polypeptide consisting of an amino acid sequence as set forth in Figure 12A (SEQ ID NO:17).

79. **(previously presented)** An isolated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence as set forth in Figure 3A (SEQ ID NO:11) wherein the nucleotide sequence does not encode the polypeptide of GenBank Accession No. AB014553.

80. **(previously presented)** An isolated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence as set forth in Figure 12A (SEQ ID NO:16).

81. **(currently amended)** An isolated polypeptide encoded by a nucleic acid molecule which is capable of hybridizing over its entire length to a nucleic acid molecule that is complementary to a nucleic acid molecule as set forth in Figure 2A (SEQ ID NO:6) or Figure 3A (SEQ ID NO:11) or Figure 12A (SEQ ID NO:17) under high stringency conditions comprising a hybridization medium of 50% (volume/volume) formamide with 0.1% bovine serum albumin/0.1% ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH6.5 with 5 X SSC at 42° C and washes at 42° C in 0.2 X SSC and 0.1% SDS, wherein the polypeptide has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22) and the polypeptide does not have the amino acid sequence of GenBank Accession No. AB014553.

82. **(currently amended)** An isolated polypeptide which is encoded by a nucleic acid molecule comprising a sequence that is at least about 95 percent identical to a nucleic acid as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 16), wherein the isolated polypeptide has at least one activity selected from stimulating T-cell proliferation and/or activation, or binding to CRP1 of Figure 13A (SEQ ID NO:22), wherein the polypeptide does not have the amino acid sequence in GenBank Accession No. AB014553.

Application. No. 09/728,420
Amdt. dated April 1, 2005
Reply to Office Action of October 1, 2004

PATENT APPLICATION

83. **(cancelled)** An isolated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence as set forth in Figure 12A (SEQ ID NO:16).

84. **(currently amended)** A polypeptide produced by a process comprising growing a culture of a host cell in suitable culture medium and isolating the polypeptide so produced, wherein the host cell comprises a nucleic acid molecule comprising a nucleic acid sequence encoding the polypeptide of Claims 56, 57, 58 or [-]59.

85. **(currently amended)** A polypeptide produced by expression of a nucleic acid molecule comprising the nucleotide sequence encoding the polypeptide of Claims 56, 57, 58 or [-]59.